

GAT017 Exclusion Criteria

Key Exclusion Criteria:

1. History of severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.
2. Has Grade ≥ 2 peripheral neuropathy
3. Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).
4. Uncontrolled, significant cardio/cerebrovascular disease, within 6 months before the first dose of study intervention.
5. Accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks before the first dose of study intervention.
6. Prior treatment with a TROP2-targeted ADC, a topoisomerase 1 inhibitor-based ADC, and/or a topoisomerase 1 inhibitor-based chemotherapy.
7. Receiving a strong inducer/inhibitor of CYP3A4 within 2 weeks of first dose of intervention and that cannot be discontinued for the duration of the study.
8. Received investigational agents, had major surgery, or significant traumatic injury within 4 weeks before the first dose of study intervention.
9. Received prior systemic anticancer therapy or radiotherapy within 2 weeks of first dose of study intervention

Note: Patients with radiation-related toxicities requiring corticosteroids or who have had radiation pneumonitis are also excluded

10. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years or has known active CNS metastases and/or carcinomatous meningitis
11. Active infection requiring systemic therapy.
12. Has active or history of HIV, hepatitis B and/or hepatitis C infection
13. History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study